Verona Pharma: Hits record high after lung drug's trial success

Verona Pharma

26/03/2018 15:07

** Verona Pharma's U.S.-listed shares  VRNA.O  soar 19 pct
to an all-time high of $19.03 after the of British company's
lung disease drug succeeds in a mid-stage study
    ** VRNA is the 3rd biggest pct gainer across all U.S.
exchanges and set for its best day in over 6 months
    ** Co's drug RPL554, to treat chronic obstructive pulmonary
disease (COPD) met the main goal in the study and was
well-tolerated at all dose levels  urn:newsml:reuters.com:*:nGNXb9yDz3
    ** More than 32k shares traded, ~4x their 30-DMA 
    ** Including session's gains, stock has risen 67 pct YTD

 (Reporting by Amy Caren Daniel in Bengaluru)
 ((Reuters Messaging:
Amy.CarenDaniel.thomsonreuters.com@reuters.net))